Company news

Medicenna Therapeutics Corp. (TSX:MDNA) news

Medicenna Therapeutics Corp. news releases on 6ix. Latest, Oct 5, 2026: Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1…

Medicenna Therapeutics Corp. (TSX:MDNA) news

Press releases & updates

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Medicenna Announces the Launch of a Marketed Public Offering of Securities

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Medicenna Announces Changes to Board Composition

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

Dr. Fahar Merchant acquires shares of Medicenna

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

Medicenna Therapeutics Announces Participation in Upcoming Conferences

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

Medicenna Strengthens Intellectual Property Portfolio with&#xA0;Five Patents Granted for its IL-2 and IL-4 Superkines

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Medicenna to Present at Jones Healthcare and Technology Innovation Conference

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Reports MDNA11's Compelling Anti-Cancer Activity is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Canadian Investment Regulatory Organization Trade Resumption - MDNA

Canadian Investment Regulatory Organization Trading Halt - MDNA

Medicenna to Present at Raymond James Human Healthcare Innovation Conference

47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines